Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Sydney Otomancek
AI in HEOR: Three Ways Artificial Intelligence Is Accelerating Evidence Generation
By Niyati Parikh, VP, Product Readiness, Panalgo, and Mike Munsell, Director, RWD and HEOR, Panalgo Evidence generation in health economics and outcomes research (HEOR) has long been a rigorous, but time-intensive process. From literature reviews to cohort design, researchers have traditionally spent weeks or even months on foundational tasks before analysis could even begin. Today, AI is beginning to reshape that workflow.
FDA and Medtech Industry Reach Preliminary MDUFA VI Agreement
The FDA and the medical device industry have reached an “agreement in principle” for the sixth Medical Device User Fee Amendments (MDUFA VI), set to run from 2027 to 2032. A primary focus of the deal is a commitment to hire a “substantial” number of new review staff to address chronic understaffing at the Center for Devices and Radiological Health. This move ensures the agency has the resources to maintain efficient review timelines and build upon the hiring targets established in previous cycles.
The ICHRA Shift: Insurance Growth Meets Market Volatility
Individual Coverage Health Reimbursement Arrangements (ICHRAs) are gaining momentum as a strategic alternative to traditional group health plans, which have seen stagnating enrollment. By providing employees with tax-free funds to purchase their own ACA marketplace plans, employers gain predictable “defined contribution” costs while shifting the burden of rising premiums.
Steve Ubl to Step Down as Longest-Serving CEO of PhRMA
After more than a decade leading the Pharmaceutical Research and Manufacturers of America (PhRMA), Steve Ubl will step down as CEO at the end of 2026. As the longest-serving leader in the organization’s 68-year history, Ubl navigated the industry through a transformative era defined by the Inflation Reduction Act and recent drug pricing initiatives under President Trump.
The End of the Road: IO Biotech to File for Bankruptcy Following Trial Failure
Danish biotech firm IO Biotech has announced its intention to seek bankruptcy protection and shut down operations following the failure of its lead cancer vaccine candidate. The decision, disclosed in a recent SEC filing, comes after the company’s “off-the-shelf” vaccine failed to reach statistical significance in a pivotal Phase 3 trial for advanced melanoma.
Biogen has agreed to acquire Apellis Pharmaceuticals for $5.6 billion, gaining two marketed drugs, Syfovre and Empaveli, to diversify its portfolio beyond neuroscience. This strategic move leverages Apellis’ expertise in the “C3” immune protein and nephrology, strengthening Biogen’s commercial pipeline in rare diseases and immunology. The deal features a 140% share premium and contingent value rights tied to Syfovre hitting specific sales milestones through 2031.
Strait of Hormuz Closure Triggers Global Manufacturing Price Surge
The ongoing closure of the Strait of Hormuz has triggered a massive disruption in global supply chains, causing crude oil prices to surge by 47% and essential manufacturing materials like polypropylene to jump 24%. As a critical choke point for 30% of global seaborne oil, the disruption is forcing manufacturers to reroute shipments and face soaring transportation and energy costs.
Abbott Finalizing $21 Billion Acquisition of Exact Sciences
Abbott is set to close its $21 billion acquisition of cancer-screening specialist Exact Sciences on Monday, having successfully secured all necessary regulatory approvals. This landmark deal, the largest in the medtech sector over the past year, integrates Exact Sciences’ prominent diagnostic tools—including the noninvasive Cologuard test and emerging blood-based cancer screenings—into Abbott’s global portfolio.
Roche Ends Trial for SMA Drug Emugrobart, Handing Market Edge to Scholar Rock
Roche and its subsidiary Genentech have officially halted the development of emugrobart, an investigational anti-myostatin therapy for Spinal Muscular Atrophy (SMA), following disappointing Phase 2/3 MANATEE study results. While the drug was well-tolerated with no safety concerns, it failed to provide the consistent improvements in muscle growth and motor function expected when combined with the company’s existing drug, Evrysdi.
Nadia Care Raises $12M to Expand Medicaid-Focused Maternal Care
Maternal care startup Nadia Care has secured a $12 million Series A extension led by Valtruis to fund its strategic pivot from commercial insurance to a Medicaid-only model. By focusing exclusively on the 40% of U.S. births covered by Medicaid, the company uses a hybrid virtual and in-person approach to meet patients in accessible locations like cafes or supermarkets, effectively bypassing the transportation and scheduling barriers faced by hourly workers.
FDA Modernizes Safety Monitoring with Unified AEMS Platform
The U.S. Food and Drug Administration has launched the FDA Adverse Event Monitoring System (AEMS), a unified platform designed to replace a fragmented patchwork of seven legacy databases. This modernization effort consolidates reports for drugs, vaccines, cosmetics, and food into a single, real-time dashboard, replacing outdated systems like FAERS and VAERS.
Rare Disease Drug Sales Projected to Reach $409B by 2032 Despite FDA Volatility
Despite a volatile regulatory landscape and stiff competition from mainstream blockbuster treatments like obesity drugs, the global orphan drug market is projected to surge past $400 billion by 2032. According to Evaluate’s 2026 report, rare disease treatments will account for over 21% of all prescription drug sales, driven by leaders like Johnson & Johnson and argenx.
BioNTech Founders Sahin and Türeci to Step Down for New mRNA Venture
BioNTech founders Ugur Sahin and Özlem Türeci will step down by the end of 2026 to launch a new, independent startup focused on next-generation mRNA discovery. While BioNTech will retain a minority stake and provide technology rights to the new venture, it will no longer provide capital support. This transition marks a pivot for the founders back to early-stage innovation, leaving BioNTech to focus on its maturing portfolio of late-stage cancer therapies.
FDA Disputes uniQure’s Claims on Sham-Controlled Trials for AMT-130
The FDA has publicly challenged uniQure’s stance on the trial requirements for its Huntington’s therapy, AMT-130. While uniQure argued that a sham-controlled study would require unethical “burr holes” and prolonged anesthesia, a senior FDA official clarified that the agency only requested “one to three nicks” in the scalp to maintain the study’s blind.
Moderna Settles $2.25B Patent Dispute Over mRNA Technology
Moderna has agreed to pay up to $2.25 billion to Arbutus Biopharma and Genevant Sciences to settle a high-stakes legal battle over the “lipid nanoparticle” (LNP) technology used in its mRNA vaccines. The deal includes an immediate $950 million payment, while another $1.3 billion remains subject to appeal.
Novo Nordisk Announces $501M Ireland Expansion for Wegovy Pill Production
Novo Nordisk has announced a €432 million ($501 million) investment to expand its manufacturing facility in Athlone, Ireland, specifically targeting the production of its oral GLP-1 obesity medication, the Wegovy pill.
Moderna’s Combo mRNA Vaccine Nears European Milestone
The European Medicines Agency’s CHMP has recommended the approval of mCombriax, Moderna’s first-of-its-kind mRNA combination vaccine targeting both COVID-19 and seasonal influenza. Tailored for adults aged 50 and older, the recommendation is backed by Phase III clinical data showing that a single dose elicited significantly higher immune responses compared to co-administered standalone vaccines.
The FDA Standoff: Clinical Rigor vs. Patient Reality
Rare disease advocates and biotechs are urging the FDA for “regulatory flexibility” after several therapies for ultra-rare conditions were rejected. During recent Congressional meetings, groups like the United Mitochondrial Disease Foundation argued that traditional, randomized trials are often impossible for tiny patient populations.
Novo Nordisk Strikes $2.1B Obesity Deal Following Clinical Setback
Novo Nordisk has entered a $2.1 billion partnership with Boston-based Vivtex to develop oral weight-loss therapies. This move follows a clinical trial where Novo’s next-generation asset, CagriSema, was outperformed by Eli Lilly’s Zepbound. By leveraging Vivtex’s “GI tract on a chip” screening platform, Novo aims to convert injectable biologics into convenient pill formulations to regain its competitive edge.
Gilead Sciences to Acquire Arcellx in $7.8B Strategic Cell Therapy Expansion
Gilead Sciences has reached a definitive agreement to acquire its long-term partner, Arcellx, in a deal valued at approximately $7.8 billion. The acquisition is centered on “anito-cel,” an experimental CAR-T cell therapy for multiple myeloma that has demonstrated a remarkable 96% response rate in late-stage clinical trials.
Regulatory Shift: FDA Leadership to Probe SSRI and RSV Antibody Safety
Tracy Beth Høeg, the newly appointed head of the FDA’s Center for Drug Evaluation and Research (CDER), has announced plans to scrutinize the safety of SSRI antidepressants during pregnancy and RSV monoclonal antibodies in infants. Despite existing clinical consensus and pushback from major medical organizations like ACOG, Høeg expressed concerns regarding potential birth defects and seizure risks.
Telehealth Reaches Equilibrium: Post-Pandemic Trends in Primary Care
Following the massive surge in virtual care during the COVID-19 pandemic, telehealth utilization in primary care has finally stabilized. Data from Epic Research, covering over 400 million visits between 2022 and 2025, shows that while virtual visits peaked during the public health emergency, they have now settled into a steady “equilibrium” of approximately 6% to 7% of all primary care encounters.
FDA Shifts to Single-Trial Standard for Drug Approvals
The U.S. Food and Drug Administration (FDA) is transitioning to a new default standard that replaces the long-standing requirement for two pivotal clinical trials with a single, robust study supplemented by confirmatory evidence. Announced by FDA officials Marty Makary and Vinay Prasad, the policy aims to accelerate drug development and reduce costs, noting that a single pivotal study can range from $30 million to $150 million.
Compass Pathways Phase 3 Psilocybin Results & FDA Approval Timeline
Compass Pathways has reported positive results from its second large-scale Phase 3 trial of COMP360, a synthetic psilocybin treatment for treatment-resistant depression (TRD). The study demonstrated that a high dose of the compound led to a statistically significant and clinically meaningful reduction in depression symptoms compared to a control group, with effects appearing as early as the day after administration.
Long-Term Efficacy: Beyfortus Reduces Infant RSV Hospitalizations Across Two Seasons
New real-world data from the NIRSE-GAL study demonstrates that Sanofi’s Beyfortus (nirsevimab) provides significant protection against respiratory syncytial virus (RSV) well beyond an infant’s first season. The study revealed an 85.9% reduction in RSV-related hospitalizations for infants immunized in their first season, with a persistent benefit leading to 55.3% fewer hospitalizations during the second season.
European Life Sciences Coalition Launched to Enhance Investment and Competitiveness
A new European Life Sciences Coalition has been established in Brussels to address the systemic investment gaps and regulatory hurdles hindering the continent’s biotechnology sector. Formed in partnership with Invest Europe and representing firms managing over €24 billion in assets, the group aims to mobilize greater public and private capital to support the scaling of innovative companies.
AstraZeneca CEO Maintains UK Investment Freeze Despite New Pricing Deal
AstraZeneca CEO Pascal Soriot has welcomed a recent UK-US drug pricing deal as a “positive step,” yet he remains hesitant to unfreeze a paused £200m investment in Cambridge. While the deal aims to improve NHS access to new treatments, Soriot suggests the UK’s ecosystem still lags behind the US and China, where the company is currently pouring billions into expansion.
FDA Rejection Stalls Moderna’s mRNA Flu Vaccine Ambitions
The FDA has issued a “refuse-to-file” letter for Moderna’s mRNA-based influenza vaccine (mRNA-1010), citing concerns over the clinical trial’s design.
Takeda and Iambic Forge $1.7 Billion AI-Driven Drug Discovery Pact
Takeda Pharmaceutical has entered into a multiyear collaboration with Iambic Therapeutics, a deal potentially worth over $1.7 billion, to accelerate the discovery of small molecule drugs for cancer, digestive, and immune disorders. The partnership grants Takeda access to Iambic’s AI-driven platforms, which are designed to predict protein-receptor interactions and streamline the development of new medicines.
TrumpRx Set to Launch: A New Era for Cash-Pay Prescription Drugs
The Trump administration is set to launch TrumpRx, a government-run website designed to connect patients with discounted cash-pay options for prescription drugs. Developed in collaboration with CMS and featuring technology from GoodRx, the portal facilitates “most favored nation” pricing deals with major drugmakers like Pfizer and AbbVie.
AstraZeneca Harmonizes Global Listings with New York Stock Exchange Debut
AstraZeneca has officially transitioned its U.S. listing to the New York Stock Exchange (NYSE), harmonizing its trading structure across the New York, London, and Stockholm exchanges under the ticker “AZN.” This strategic move aims to broaden the company’s investor base by tapping into the world’s largest capital market to fuel its ambitious 2030 growth strategy.
Amgen Defies FDA Request to Withdraw Tavneos Amid Data Integrity Concerns
Amgen has rejected an FDA request to voluntarily withdraw its rare disease drug, Tavneos, following concerns over Phase 3 clinical trial data integrity and potential liver toxicity. While European regulators are also re-reviewing the drug, Amgen maintains that years of Real World Evidence and a lack of alternative treatments for ANCA-associated vasculitis justify keeping it on the market. The standoff involves a rapidly growing asset that generated $459 million in 2025 sales.
As Medicare drug price negotiation moves from policy concept to operational reality, attention is beginning to shift from implementation mechanics to forward-looking implications. Now, in 2026, the Inflation Reduction Act (IRA) will no longer be judged primarily by its statutory design, but by how effectively it reshapes drug pricing, evidence standards, and incentives across the healthcare system.
What the Inflation Reduction Act Will Mean for Medicare Drug Pricing in 2026 - HealthEconomics.com
As Medicare drug price negotiation moves from policy concept to operational reality, attention is beginning to shift from implementation mechanics to forward-looking implications. Now, in 2026, the Inflation Reduction Act (IRA) will no longer be judged primarily by its statutory design, but by how effectively it reshapes drug pricing, evidence standards, and incentives across the healthcare system.
Humana Leverages Google Cloud AI to Enhance Call Center Operations
Humana has launched “Agent Assist,” a generative AI tool developed with Google Cloud designed to support its 20,000 call center employees. The technology provides real-time conversation summaries and surfaces critical member data, such as eligibility and benefit details, allowing agents to focus on the caller rather than manual note-taking.
FDA Launches PreCheck Pilot to Onshore Pharmaceutical Manufacturing
The FDA has officially launched the FDA PreCheck pilot program, a strategic initiative designed to strengthen the domestic pharmaceutical supply chain and incentivize “onshoring” of drug production.
EU and India Finalize Landmark Free Trade Agreement to Slash Tariffs
The European Union and India have finalized a landmark free trade agreement, dubbed the “mother of all deals,” effectively creating a free trade zone for 2 billion people. The pact eliminates or slashes tariffs on over 96% of traded goods, including a move to zero duties for pharmaceuticals, chemicals, and industrial machinery. Beyond trade, the agreement serves as a strategic counterweight to global economic pressures from China and the U.S. while deepening bilateral security and research ties.
Sanofi CEO Defends Vaccines as "Number One Gift to Public Health" Amid U.S. Policy Shifts
Despite a 2.5% dip in vaccine sales for 2025, Sanofi CEO Paul Hudson remains committed to immunization as a cornerstone of public health. The decline was largely driven by a challenging U.S. landscape, where policy changes and public skepticism, fueled by Health Secretary Robert F. Kennedy Jr., have impacted routine vaccination schedules and access.
Automated Cell Therapy Manufacturing: Cellares Secures $257M to Scale Global Production
Cellares has raised $257 million in Series D funding to complete the construction of automated cell therapy manufacturing plants in the U.S., Japan, and the Netherlands. The company’s proprietary “Cell Shuttle” platform integrates and automates the production process, aiming to significantly reduce labor costs, facility requirements, and the high failure rates typically associated with CAR T therapies.
CMS Proposes Major Crackdown on Medicare Advantage "Upcoding"
The Trump administration’s proposed 2027 payment rule targets “upcoding” by excluding “unlinked” chart reviews from Medicare Advantage (MA) risk scoring. Currently, insurers can mine medical records for extra diagnoses to inflate reimbursements—a practice linked to an estimated $24 billion in annual overpayments. By requiring diagnoses to be tied to actual medical visits, CMS expects to save the program over $7 billion in 2027.
Rare Disease Biotechs Face Crisis Over Expiring FDA Vouchers
The rare disease biotech sector is facing a massive financial crisis following the 2024 lapse of the FDA’s Priority Review Voucher (PRV) program. A report by the Rare Disease Company Coalition warns that if Congress fails to reauthorize the program immediately, the industry stands to lose $4 billion in potential reinvestment revenue. These vouchers, which can be sold for hundreds of millions of dollars, serve as a vital lifeline for cash-strapped startups.
The Impact of Medicare Part D on Antimicrobial Resistance
Ang (2026) investigates the causal link between the 2006 introduction of Medicare Part D and hospital admissions for antimicrobial-resistant (AMR) infections in the United States. While antimicrobial resistance is often associated with the overuse of antibiotics, the author explores the “under-utilization” hypothesis: that financial barriers previously prevented seniors from filling prescriptions, allowing infections to linger and develop resistance.
Misuse of Medical AI Ranked as Top 2026 Health Hazard
The nonprofit organization ECRI has named the misuse of artificial intelligence chatbots as the primary health technology hazard for 2026. While large language models (LLMs) like ChatGPT are not validated for clinical use, a significant portion of the population increasingly relies on them for medical advice.
EU Parliament Reaches Key Milestone on Critical Medicines Act to Tackle Drug Shortages
The European Parliament has reached a significant milestone by advancing proposals for the Critical Medicines Act, a legislative initiative designed to combat chronic medicine shortages across the region. A central feature of the act is a strategic shift in public procurement; EU member states will no longer be permitted to use price as the sole factor in awarding contracts.
Geopolitical Tug-of-War: Trump’s Greenland Ambitions Threaten Pharma Trade Stability
President Trump has escalated his bid to acquire Greenland by threatening a new 10% tariff on eight European nations, including Germany and the U.K., effective February 1. This “Greenland tax” is designed to increase to 25% by June unless a deal for the territory is reached, directly retaliating against EU pushback and recent troop deployments to the region.
Novo Nordisk Gains Momentum with Oral Wegovy Launch Amid Eli Lilly Rivalry
Despite Novo Nordisk’s early dominance in the GLP-1 sector, the company has recently trailed behind Eli Lilly, which recently became the first pharmaceutical firm to reach a $1 trillion market cap. However, the launch of Novo’s oral version of Wegovy has provided a significant boost, securing 3,100 scripts in its first week—outperforming the initial launch week of Lilly’s Zepbound.
Trump Reveals "Great Healthcare Plan" Targeting ACA Premiums and Drug Prices
President Trump has introduced the “Great Healthcare Plan,” a one-page framework designed to lower costs following the 2026 expiration of ACA subsidies. The proposal shifts federal aid from insurers to consumers via direct HSA deposits, revives cost-sharing reduction payments, and codifies “most favored nation” drug pricing deals. It also mandates aggressive price transparency, requiring insurers to publish plain-English rate comparisons and claim rejection statistics.
Oxford Biomedica in Takeover Talks with Private Equity Firm EQT
Oxford Biomedica, a leading contract manufacturer specializing in viral vectors for cell and gene therapies, has confirmed it is in preliminary discussions regarding a potential takeover by the private equity group EQT. While the company previously rejected multiple unsolicited bids for being too low, it is now evaluating whether EQT can provide a cash offer that reflects the firm’s true value and growth prospects. EQT has until February 11 to formally announce its intent to bid or walk away.
Bayer Collaborates with Cradle to Scale Generative AI in Antibody Discovery
Bayer has entered a three-year strategic collaboration with Cradle to integrate its generative AI software into Bayer’s biologics R&D workflow. The partnership aims to enhance the discovery and optimization of therapeutic antibodies by utilizing “lab-in-the-loop” AI to design higher-quality molecules.
FDA Releases Draft Guidance on Bayesian Methods to Accelerate Drug Development
The U.S. Food and Drug Administration has released draft guidance aimed at increasing the use of Bayesian methodologies in clinical trials for drugs and biologics. Unlike traditional statistical frameworks, Bayesian analysis allows developers to combine current study data with prior information—such as previous clinical trials or real-world evidence—to draw conclusions about safety and efficacy.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Sydney
Contact Sydney, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack